<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1197" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1197/" /><meta name="ncbi_pagename" content="Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL) - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL) - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL)" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/03/12" /><meta name="citation_author" content="Juha Paloneva" /><meta name="citation_author" content="Taina Autti" /><meta name="citation_author" content="Panu Hakola" /><meta name="citation_author" content="Matti J Haltia" /><meta name="citation_pmid" content="20301376" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1197/" /><meta name="citation_keywords" content="Nasu-Hakola Disease" /><meta name="citation_keywords" content="Nasu-Hakola Disease" /><meta name="citation_keywords" content="Triggering receptor expressed on myeloid cells 2" /><meta name="citation_keywords" content="TYRO protein tyrosine kinase-binding protein" /><meta name="citation_keywords" content="TREM2" /><meta name="citation_keywords" content="TYROBP" /><meta name="citation_keywords" content="Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL)" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Juha Paloneva" /><meta name="DC.Contributor" content="Taina Autti" /><meta name="DC.Contributor" content="Panu Hakola" /><meta name="DC.Contributor" content="Matti J Haltia" /><meta name="DC.Date" content="2015/03/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1197/" /><meta name="description" content="Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) is characterized by fractures (resulting from radiologically demonstrable polycystic osseous lesions), frontal lobe syndrome, and progressive presenile dementia beginning in the fourth decade. The clinical course of PLOSL can be divided into four stages: (1) The latent stage is characterized by normal early development. (2) The osseous stage (3rd decade of life) is characterized by pain and tenderness, mostly in ankles and feet, usually following strain or injury. Fractures are typically diagnosed several years later, most commonly in the bones of the extremities. (3) In the early neurologic stage (4th decade of life), a change of personality begins to develop insidiously. Affected individuals show a frontal lobe syndrome (loss of judgment, euphoria, loss of social inhibitions, disturbance of concentration, and lack of insight, libido, and motor persistence) leading to serious social problems. (4) The late neurologic stage is characterized by progressive dementia and loss of mobility. Death usually occurs before age 50 years." /><meta name="og:title" content="Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL)" /><meta name="og:type" content="book" /><meta name="og:description" content="Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) is characterized by fractures (resulting from radiologically demonstrable polycystic osseous lesions), frontal lobe syndrome, and progressive presenile dementia beginning in the fourth decade. The clinical course of PLOSL can be divided into four stages: (1) The latent stage is characterized by normal early development. (2) The osseous stage (3rd decade of life) is characterized by pain and tenderness, mostly in ankles and feet, usually following strain or injury. Fractures are typically diagnosed several years later, most commonly in the bones of the extremities. (3) In the early neurologic stage (4th decade of life), a change of personality begins to develop insidiously. Affected individuals show a frontal lobe syndrome (loss of judgment, euphoria, loss of social inhibitions, disturbance of concentration, and lack of insight, libido, and motor persistence) leading to serious social problems. (4) The late neurologic stage is characterized by progressive dementia and loss of mobility. Death usually occurs before age 50 years." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1197/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/plosl/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1197/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A67C4E040AEB10000000001590083.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1197_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1197_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pkd-ar/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/poly/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1197_"><span class="title" itemprop="name">Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL)</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Nasu-Hakola Disease</div><p class="contrib-group"><span itemprop="author">Juha Paloneva</span>, MD, PhD, <span itemprop="author">Taina Autti</span>, MD, PhD, <span itemprop="author">Panu Hakola</span>, MD, PhD, and <span itemprop="author">Matti J Haltia</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1197_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1197_ai__"><div class="contrib half_rhythm"><span itemprop="author">Juha Paloneva</span>, MD, PhD<div class="affiliation small">Department of Surgery<br />Central Finland Hospital<br />Jyvaskyla, Finland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="if.tenmif@avenolap.ahuj" class="oemail">if.tenmif@avenolap.ahuj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Taina Autti</span>, MD, PhD<div class="affiliation small">University of Helsinki<br />Helsinki Medical Imaging Center<br />Helsinki, Finland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="if.suh@ittua.aniatttua" class="oemail">if.suh@ittua.aniatttua</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Panu Hakola</span>, MD, PhD<div class="affiliation small">Department of Forensic Medicine<br />Niuvanniemi Hospital<br />University of Kuopio<br />Kuopio, Finland</div></div><div class="contrib half_rhythm"><span itemprop="author">Matti J Haltia</span>, MD, PhD<div class="affiliation small">Department of Pathology<br />Haartman Institute<br />University of Helsinki<br />Helsinki, Finland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="if.iknisleh@aitlah.j.ittam" class="oemail">if.iknisleh@aitlah.j.ittam</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 24, 2002</span>; Last Update: <span itemprop="dateModified">March 12, 2015</span>.</p><p><em>Estimated reading time: 24 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="plosl.Summary" itemprop="description"><h2 id="_plosl_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) is characterized by fractures (resulting from radiologically demonstrable polycystic osseous lesions), frontal lobe syndrome, and progressive presenile dementia beginning in the fourth decade. The clinical course of PLOSL can be divided into four stages: (1) The latent stage is characterized by normal early development. (2) The osseous stage (3rd decade of life) is characterized by pain and tenderness, mostly in ankles and feet, usually following strain or injury. Fractures are typically diagnosed several years later, most commonly in the bones of the extremities. (3) In the early neurologic stage (4th decade of life), a change of personality begins to develop insidiously. Affected individuals show a frontal lobe syndrome (loss of judgment, euphoria, loss of social inhibitions, disturbance of concentration, and lack of insight, libido, and motor persistence) leading to serious social problems. (4) The late neurologic stage is characterized by progressive dementia and loss of mobility. Death usually occurs before age 50 years.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The combination of radiologically demonstrable polycystic osseous lesions, frontal lobe syndrome, and progressive presenile dementia beginning in the fourth decade is diagnostic. Fractures of the wrists or ankles after minor trauma with typical polycystic osseous lesions identified on x-ray examination suggest the possibility of PLOSL. In uncertain cases, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> helps to establish the diagnosis. <i>TYROBP</i> (<i>DAP12</i>) and <i>TREM2</i> are the only two genes in which pathogenic variants are known to cause PLOSL.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment is symptomatic. Orthopedic surgery and/or devices may be of value in individual cases. Antiepileptic drugs can be used to prevent epileptic seizures and secondary worsening of the condition.</p><p><i>Prevention of secondary complications:</i> Some of the social consequences of PLOSL may be avoided if family members are informed early about the nature of the disorder.</p><p><i>Surveillance</i>: Intervals for follow up of bone lesions and neurologic and psychiatric manifestations must be determined individually.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>PLOSL is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p></div></div><div id="plosl.Diagnosis"><h2 id="_plosl_Diagnosis_">Diagnosis</h2><div id="plosl.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Diagnosis of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) should be suspected in individuals with the combination of the following features:</p><ul><li class="half_rhythm"><div><b>Radiologically demonstrable polycystic osseous lesions</b> and fractures of the wrists and ankles after minor trauma at the mean age of 27 years (range 18-33 years) [<a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>]. Cyst-like lesions and loss of bone trabeculae are most conspicuous in the fingers and in the carpal and tarsal bones (see <a class="figpopup" href="/books/NBK1197/figure/plosl.F1/?report=objectonly" target="object" rid-figpopup="figploslF1" rid-ob="figobploslF1">Figure 1</a> and <a class="figpopup" href="/books/NBK1197/figure/plosl.F2/?report=objectonly" target="object" rid-figpopup="figploslF2" rid-ob="figobploslF2">Figure 2</a>) [<a class="bk_pop" href="#plosl.REF.m_kel_.1982.51">M&#x000e4;kel&#x000e4; et al 1982</a>, <a class="bk_pop" href="#plosl.REF.nwawka.2014.1449">Nwawka et al 2014</a>]. See also <a class="figpopup" href="/books/NBK1197/figure/plosl.F2/?report=objectonly" target="object" rid-figpopup="figploslF2" rid-ob="figobploslF2">Figures 2</a> and <a class="figpopup" href="/books/NBK1197/figure/plosl.F3/?report=objectonly" target="object" rid-figpopup="figploslF3" rid-ob="figobploslF3">3</a> in <a class="bk_pop" href="#plosl.REF.nwawka.2014.1449">Nwawka et al [2014]</a> (<a href="http://link.springer.com/article/10.1007/s00256-014-1887-5/fulltext.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>). If an individual has multiple lytic or cyst-like lesions on radiograph primarily in the distal extremities, CT and MRI are useful in making an accurate diagnosis [<a class="bk_pop" href="#plosl.REF.nwawka.2014.1449">Nwawka et al 2014</a>].</div></li><li class="half_rhythm"><div><b>Frontal lobe syndrome</b> in the fourth decade manifested by euphoria and loss of judgment and social inhibitions</div></li><li class="half_rhythm"><div><b>Progressive presenile dementia</b> beginning in the fourth decade. Dementia is mild at the onset of neurologic symptoms. The disease culminates in severe dementia; <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals typically die before age 50 years.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figploslF1" co-legend-rid="figlgndploslF1"><a href="/books/NBK1197/figure/plosl.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figploslF1" rid-ob="figobploslF1"><img class="small-thumb" src="/books/NBK1197/bin/plosl-Image001.gif" src-large="/books/NBK1197/bin/plosl-Image001.jpg" alt="Figure 1. . A radiograph of the hand of a person with PLOSL demonstrates multiple cyst-like lesions and loss of bone trabeculae." /></a><div class="icnblk_cntnt" id="figlgndploslF1"><h4 id="plosl.F1"><a href="/books/NBK1197/figure/plosl.F1/?report=objectonly" target="object" rid-ob="figobploslF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">A radiograph of the hand of a person with PLOSL demonstrates multiple cyst-like lesions and loss of bone trabeculae. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figploslF2" co-legend-rid="figlgndploslF2"><a href="/books/NBK1197/figure/plosl.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figploslF2" rid-ob="figobploslF2"><img class="small-thumb" src="/books/NBK1197/bin/plosl-Image002.gif" src-large="/books/NBK1197/bin/plosl-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndploslF2"><h4 id="plosl.F2"><a href="/books/NBK1197/figure/plosl.F2/?report=objectonly" target="object" rid-ob="figobploslF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">A radiograph shows a well-demarcated cyst-like lesion (arrow) in the talus of a person with PLOSL, age 28 years [Paloneva et al 2001; reprinted with permission from <i>Neurology</i>] </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figploslF3" co-legend-rid="figlgndploslF3"><a href="/books/NBK1197/figure/plosl.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figploslF3" rid-ob="figobploslF3"><img class="small-thumb" src="/books/NBK1197/bin/plosl-Image003.gif" src-large="/books/NBK1197/bin/plosl-Image003.jpg" alt="Figure 3. . T2-weighted MR image of a patient age 33 years shows very low signal intensity in the putamina." /></a><div class="icnblk_cntnt" id="figlgndploslF3"><h4 id="plosl.F3"><a href="/books/NBK1197/figure/plosl.F3/?report=objectonly" target="object" rid-ob="figobploslF3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">T<sub>2</sub>-weighted MR image of a patient age 33 years shows very low signal intensity in the putamina. Signal intensities are higher in the central white matter (including internal capsules) than in the deep gray matter structures. The central white matter partially <a href="/books/NBK1197/figure/plosl.F3/?report=objectonly" target="object" rid-ob="figobploslF3">(more...)</a></p></div></div></div><div id="plosl.Testing"><h3>Testing</h3><p><b>Bone biopsy</b> is not required to establish the diagnosis. The cyst-like bone lesions are filled with lipid material that microscopically consists of characteristic 1-2 &#x000b5;m-thick lipid membranes and amorphous lipid substance.</p><p><b>Neuroradiologic examination</b> (<a class="figpopup" href="/books/NBK1197/figure/plosl.F3/?report=objectonly" target="object" rid-figpopup="figploslF3" rid-ob="figobploslF3">Figure 3</a>, <a class="figpopup" href="/books/NBK1197/figure/plosl.F4/?report=objectonly" target="object" rid-figpopup="figploslF4" rid-ob="figobploslF4">Figure 4</a>, <a class="figpopup" href="/books/NBK1197/figure/plosl.F5/?report=objectonly" target="object" rid-figpopup="figploslF5" rid-ob="figobploslF5">Figure 5</a>)</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figploslF4" co-legend-rid="figlgndploslF4"><a href="/books/NBK1197/figure/plosl.F4/?report=objectonly" target="object" title="Figure 4. " class="img_link icnblk_img figpopup" rid-figpopup="figploslF4" rid-ob="figobploslF4"><img class="small-thumb" src="/books/NBK1197/bin/plosl-Image004.gif" src-large="/books/NBK1197/bin/plosl-Image004.jpg" alt="Figure 4. . T2-weighted MR image of a patient age 32 years displays severely enlarged cerebral sulci and lateral ventricles." /></a><div class="icnblk_cntnt" id="figlgndploslF4"><h4 id="plosl.F4"><a href="/books/NBK1197/figure/plosl.F4/?report=objectonly" target="object" rid-ob="figobploslF4">Figure 4. </a></h4><p class="float-caption no_bottom_margin">T<sub>2</sub>-weighted MR image of a patient age 32 years displays severely enlarged cerebral sulci and lateral ventricles. Note high periventricular signal intensity spreading toward periphery. The arcuate fibers are partly spared [Paloneva et al 2001; reprinted <a href="/books/NBK1197/figure/plosl.F4/?report=objectonly" target="object" rid-ob="figobploslF4">(more...)</a></p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figploslF5" co-legend-rid="figlgndploslF5"><a href="/books/NBK1197/figure/plosl.F5/?report=objectonly" target="object" title="Figure 5. " class="img_link icnblk_img figpopup" rid-figpopup="figploslF5" rid-ob="figobploslF5"><img class="small-thumb" src="/books/NBK1197/bin/plosl-Image005.gif" src-large="/books/NBK1197/bin/plosl-Image005.jpg" alt="Figure 5. . Brain MRI." /></a><div class="icnblk_cntnt" id="figlgndploslF5"><h4 id="plosl.F5"><a href="/books/NBK1197/figure/plosl.F5/?report=objectonly" target="object" rid-ob="figobploslF5">Figure 5. </a></h4><p class="float-caption no_bottom_margin">Brain MRI. High-intensity lesions in the bilateral periventricular white matter on an axial FLAIR image (TR: 8000 ms, TE: 120 ms) [Kuroda et al 2007; reprinted with permission from <i>Elsevier</i>] </p></div></div><ul><li class="half_rhythm"><div><b>Cerebral atrophy</b> (dilated ventricles in addition with the atrophy of the basal ganglia and thalamus, prominent sulci or thin corpus callosum) of varying degree is a constant finding on CT and MRI and is evident even before the appearance of neuropsychiatric symptoms. In addition to progressive cerebral atrophy, cerebellar atrophy may appear [<a class="bk_pop" href="#plosl.REF.araki.1991.793">Araki et al 1991</a>, <a class="bk_pop" href="#plosl.REF.hakola.1993.370">Hakola &#x00026; Puranen 1993</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>, <a class="bk_pop" href="#plosl.REF.solje.2014.1780.e13">Solje et al 2014</a>].</div></li><li class="half_rhythm"><div><b>Bilateral calcifications of the basal ganglia</b> are a common finding on CT. Most often, they are situated in the putamina. Calcifications, atrophy of the basal ganglia, and progressively increasing and abnormally high bicaudate ratios may occur before CNS symptoms [<a class="bk_pop" href="#plosl.REF.bird.1983.81">Bird et al 1983</a>, <a class="bk_pop" href="#plosl.REF.araki.1991.793">Araki et al 1991</a>, <a class="bk_pop" href="#plosl.REF.hakola.1993.370">Hakola &#x00026; Puranen 1993</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>]. The basal ganglia and thalamus, particularly the putamina, may show very low signal intensities on T<sub>2</sub>-weighted MR images [<a class="bk_pop" href="#plosl.REF.araki.1991.793">Araki et al 1991</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</div></li><li class="half_rhythm"><div><b>Increased signal intensities of the cerebral white matter</b> are usually found on T<sub>2</sub>-weighted images after the appearance of clinical CNS symptoms. These white matter changes are diffuse and have no region of predilection, apart from the frontal lobes. The changes are usually centrally located (periventricular white matter, centrum semiovale, internal capsules). As the disease progresses, the high periventricular signal intensity spreads toward the periphery sparing most of the arcuate fibers. In some instances, the white matter changes also extend to the cortex. However, the white matter may look normal in some individuals with CNS symptoms [<a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>].</div></li><li class="half_rhythm"><div><b>SPECT and PET findings</b> are variable. Hypoperfusion of the cortical areas, thalamus, and basal ganglia have been reported [<a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>, <a class="bk_pop" href="#plosl.REF.takeshita.2005.309">Takeshita et al 2005</a>].</div></li></ul><p><b>Electroencephalogram</b> is normal early in the disease. With advancing disease, individuals show accentuation of theta and delta activity. Initially, theta is typically rhythmic, 6-8 Hz, dominating in the centrotemporal areas; later, diffuse slowing becomes evident. In the late stage of the disease, irritative activity usually appears on EEG [<a class="bk_pop" href="#plosl.REF.bird.1983.81">Bird et al 1983</a>, <a class="bk_pop" href="#plosl.REF.hakola.1983.515">Hakola &#x00026; Partanen 1983</a>, <a class="bk_pop" href="#plosl.REF.motohashi.1995.549">Motohashi et al 1995</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>].</p></div><div id="plosl.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of PLOSL is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in either <i>TREM2</i> or <i>TYROBP</i> (see <a class="figpopup" href="/books/NBK1197/table/plosl.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figploslTmoleculargenetictestingusedi" rid-ob="figobploslTmoleculargenetictestingusedi">Table 1</a>).</p><p>Molecular testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></b>
<b>testing.</b> The order of testing is based on the individual's ethnicity. In individuals outside of Finland and Japan, pathogenic variants in <i>TREM2</i> appear to be more frequent than in <i>TYROBP</i> [<a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</p><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin">Sequence analysis of each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> is performed first.</p></dd><dt>2.</dt><dd><p class="no_top_margin">If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> is performed next.</p></dd></dl><p><b>A</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>TREM2</i> and <i>TYROBP</i> and other genes of interest (see <a href="#plosl.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes the genes in listed in <a class="figpopup" href="/books/NBK1197/table/plosl.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figploslTmoleculargenetictestingusedi" rid-ob="figobploslTmoleculargenetictestingusedi">Table 1</a>) fails to confirm a diagnosis in an individual with features of PLOSL. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="plosl.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1197/table/plosl.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__plosl.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion of PLOSL Attributed to Mutation of This Gene</th><th id="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th></tr></thead><tbody><tr><td headers="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TREM2</i></td><td headers="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>2,&#x000a0;3,&#x000a0;4</sup></td></tr><tr><td headers="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_3" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TYROBP</i></td><td headers="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>2,&#x000a0;6,&#x000a0;7,&#x000a0;8</sup></td></tr><tr><td headers="hd_h_plosl.T.molecular_genetic_testing_used_i_1_1_1_3" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>5,&#x000a0;8,&#x000a0;9</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="plosl.TF.1.1"><p class="no_margin">See <a href="/books/NBK1197/#plosl.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#plosl.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>2. </dt><dd><div id="plosl.TF.1.2"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>3. </dt><dd><div id="plosl.TF.1.3"><p class="no_margin">Pathogenic variants reported in more than one family are <a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_trem2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figploslTselectedtrem2pathogenicvarian" rid-ob="figobploslTselectedtrem2pathogenicvarian">p.Trp78Ter</a> (found in 2 Swedish families) and <a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_trem2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figploslTselectedtrem2pathogenicvarian" rid-ob="figobploslTselectedtrem2pathogenicvarian">p.Val126Gly</a> (found in one Canadian family and one British family, both originating from Sri Lanka).</p></div></dd><dt>4. </dt><dd><div id="plosl.TF.1.4"><p class="no_margin">Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals tested to date are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for their <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#plosl.REF.paloneva.2000.357">Paloneva et al 2000</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</p></div></dd><dt>5. </dt><dd><div id="plosl.TF.1.5"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Included in the variety of methods that may be used are: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>6. </dt><dd><div id="plosl.TF.1.6"><p class="no_margin">Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals tested to date are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for their <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#plosl.REF.paloneva.2000.357">Paloneva et al 2000</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</p></div></dd><dt>7. </dt><dd><div id="plosl.TF.1.7"><p class="no_margin">Pathogenic variants reported in more than one family: <a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_tyrobp_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figploslTselectedtyrobppathogenicvaria" rid-ob="figobploslTselectedtyrobppathogenicvaria">p.Met48TrpfsTer6</a> (found in an unknown portion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of Japanese ethnicity); <a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_tyrobp_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figploslTselectedtyrobppathogenicvaria" rid-ob="figobploslTselectedtyrobppathogenicvaria">p.Met1Thr</a> (found in 2 Japanese families) [<a class="bk_pop" href="#plosl.REF.paloneva.2000.357">Paloneva et al 2000</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>]</p></div></dd><dt>8. </dt><dd><div id="plosl.TF.1.8"><p class="no_margin">Variant detection frequency is 100% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from Finland, unknown percentage of affected individuals from Sweden and Norway [<a class="bk_pop" href="#plosl.REF.paloneva.2000.357">Paloneva et al 2000</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</p></div></dd><dt>9. </dt><dd><div id="plosl.TF.1.9"><p class="no_margin">All Finnish individuals with PLOSL are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of exons 1-4 (c.-2897_276+1334del)<i>.</i> Deletions of exons 1-4 have also been found in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in other countries as well [<a class="bk_pop" href="#plosl.REF.paloneva.2000.357">Paloneva et al 2000</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</p></div></dd></dl></div></div></div></div></div><div id="plosl.Clinical_Characteristics"><h2 id="_plosl_Clinical_Characteristics_">Clinical Characteristics</h2><div id="plosl.Clinical_Description"><h3>Clinical Description</h3><p>The clinical course of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) can be divided into four stages: latent, osseous, early neurologic, and late neurologic [<a class="bk_pop" href="#plosl.REF.hakola.1972.1">Hakola 1972</a>, <a class="bk_pop" href="#plosl.REF.hakola.a">Hakola 1990a</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</p><p><b>Latent stage.</b> Early development is normal.</p><p><b>Osseous stage (3rd decade of life).</b> The first symptoms of PLOSL appear in early adulthood as pain and tenderness, mostly in the ankles and feet, usually following strain or a minor accident. Fractures are typically diagnosed several years later, most commonly in the bones of the extremities [<a class="bk_pop" href="#plosl.REF.m_kel_.1982.51">M&#x000e4;kel&#x000e4; et al 1982</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>]. The first fractures usually occur shortly before age 30 years; however, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may have been experiencing pain and swelling of the ankles and wrists after strain for years. The fractures heal well. It is important to note that some individuals may present with neurologic symptoms without any preceding osseous manifestations [<a class="bk_pop" href="#plosl.REF.matsuo.1982.123">Matsuo et al 1982</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>, <a class="bk_pop" href="#plosl.REF.chouery.2008.e194">Chouery et al 2008</a>, <a class="bk_pop" href="#plosl.REF.bock.2013.115">Bock et al 2013</a>].</p><p><b>Early neurologic stage (4th decade of life).</b> Personality changes begin insidiously in the fourth decade. Affected individuals show progressive loss of judgment, leading to serious social consequences, including divorce, unemployment, and financial trouble [<a class="bk_pop" href="#plosl.REF.hakola.1990b.21">Hakola 1990b</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>, <a class="bk_pop" href="#plosl.REF.ilonen.2012.236">Ilonen et al 2012</a>]. Some individuals may attempt suicide. The full-blown picture of frontal lobe syndrome subsequently appears: loss of judgment; euphoria; lack of social inhibitions, including <i>Witzelsucht</i>; disturbance of concentration; and lack of insight, libido, and motor persistence.</p><p>Progressive signs of upper motor neuron involvement (spasticity, extensor plantar reflexes) are noticed. With advancing disease, lack of initiative and activity conceal the aforementioned symptoms [<a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>].</p><p>Memory disturbances begin at approximately the same age as the personality changes, and are best detectable by psychometric tests [<a class="bk_pop" href="#plosl.REF.hakola.1998.39">Hakola 1998</a>, <a class="bk_pop" href="#plosl.REF.vanhanen.2013.10">Vanhanen et al 2013</a>]. The memory disturbance is less severe than the personality change, and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals retain basic personal information until the last stage of the disease.</p><p>Other disturbances of higher cortical function, such as motor aphasia, agraphia, acalculia, and apraxia, appear only at the last stage of the disease.</p><p>Affected individuals may develop postural dyspraxia: they walk or sit in peculiar skewed postures. Involuntary athetotic or choreatic movements or myoclonic twitches are common. Individuals who reach their mid-thirties frequently experience epileptic seizures. In some individuals, impotence or lack of libido and urinary incontinence are among the first symptoms [<a class="bk_pop" href="#plosl.REF.hakola.1972.1">Hakola 1972</a>, <a class="bk_pop" href="#plosl.REF.minagawa.1985.38">Minagawa et al 1985</a>, <a class="bk_pop" href="#plosl.REF.ishigooka.1993.179">Ishigooka et al 1993</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>].</p><p><b>Late neurologic stage.</b> In the last stage of the disease, individuals lose their ability to walk and progress to a vegetative state. Primitive reflexes, such as visual and tactile grasp and mouth-opening reflexes, as well as the sucking reflex, may become noticeable. Affected individuals typically die before age 50 years [<a class="bk_pop" href="#plosl.REF.verloes.1997.753">Verloes et al 1997</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>].</p><p><b>Bone pathology.</b> The cyst-like bone lesions are filled with lipid material that microscopically consists of characteristic 1-2 &#x000b5;m-thick lipid membranes and amorphous lipid substance [<a class="bk_pop" href="#plosl.REF.nasu.1973.539">Nasu et al 1973</a>, <a class="bk_pop" href="#plosl.REF.akai.1977.802">Akai et al 1977</a>, <a class="bk_pop" href="#plosl.REF.kitajima.1989.35">Kitajima et al 1989</a>]. See <a class="figpopup" href="/books/NBK1197/figure/plosl.F6/?report=objectonly" target="object" rid-figpopup="figploslF6" rid-ob="figobploslF6">Figure 6</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figploslF6" co-legend-rid="figlgndploslF6"><a href="/books/NBK1197/figure/plosl.F6/?report=objectonly" target="object" title="Figure 6. " class="img_link icnblk_img figpopup" rid-figpopup="figploslF6" rid-ob="figobploslF6"><img class="small-thumb" src="/books/NBK1197/bin/plosl-Image006.gif" src-large="/books/NBK1197/bin/plosl-Image006.jpg" alt="Figure 6. . Contents of a cyst-like bone lesion." /></a><div class="icnblk_cntnt" id="figlgndploslF6"><h4 id="plosl.F6"><a href="/books/NBK1197/figure/plosl.F6/?report=objectonly" target="object" rid-ob="figobploslF6">Figure 6. </a></h4><p class="float-caption no_bottom_margin">Contents of a cyst-like bone lesion. Microscopically, the lesions contain (C) convoluted lipid membrane structures filled with amorphous lipid substance and (F) fat. (B) Bone trabeculae are partially preserved. Scale bar corresponds to 250 &#x003bc;m <a href="/books/NBK1197/figure/plosl.F6/?report=objectonly" target="object" rid-ob="figobploslF6">(more...)</a></p></div></div><p><b>Neuropathology.</b> Generalized cerebral gyral atrophy with frontal accentuation is observed at autopsy. The corpus callosum is abnormally thin. The central white matter is severely reduced in amount, grayish, and tough. The basal ganglia, particularly the caudate nuclei, are variably reduced in size [<a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>]. All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals show marked <i>hydrocephalus e vacuo</i>.</p><p>Histologic examination reveals scattered neurons showing features of central chromatolysis. Intraneuronal or glial pathologic inclusions have not been observed [<a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>]. Neuronal loss as well as astrocytic proliferation and hypertrophy are observed in the caudate nuclei. In addition, scattered calcospherites are seen, particularly in the putamina and globi pallidi [<a class="bk_pop" href="#plosl.REF.amano.1987.294">Amano et al 1987</a>, <a class="bk_pop" href="#plosl.REF.miyazu.1991.414">Miyazu et al 1991</a>, <a class="bk_pop" href="#plosl.REF.kalimo.1994.353">Kalimo et al 1994</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>]. Thalamic degeneration may occur [<a class="bk_pop" href="#plosl.REF.tanaka.1980.193">Tanaka 1980</a>, <a class="bk_pop" href="#plosl.REF.amano.1987.294">Amano et al 1987</a>, <a class="bk_pop" href="#plosl.REF.miyazu.1991.414">Miyazu et al 1991</a>, <a class="bk_pop" href="#plosl.REF.kobayashi.2000.98">Kobayashi et al 2000</a>]. Affected individuals show advanced loss of axons and myelin and a pronounced astrocytic reaction in the centrum semiovale, accentuated in the frontal and temporal lobes, with moderate involvement of the gyral white matter. In addition, widespread activation of microglia in the cerebral white matter is seen [<a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>]. Scattered small arterioles and capillaries in the deep frontal and temporal white matter show concentric thickening of the vascular wall with multiple thickened basement membranes and narrowing or obliteration of the lumen [<a class="bk_pop" href="#plosl.REF.kalimo.1994.353">Kalimo et al 1994</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>]. The cerebral cortices are less severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> [<a class="bk_pop" href="#plosl.REF.aoki.2011.135">Aoki et al 2011</a>].</p><p><b>Pathologic findings in other organs.</b> Characteristic lipomembranous changes have been described in systemic adipose tissue [<a class="bk_pop" href="#plosl.REF.nasu.1973.539">Nasu et al 1973</a>]. Pathologic manifestations in organs other than the CNS and the skeletal system have been insufficiently characterized.</p></div><div id="plosl.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Individuals with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants in <i>TYROBP</i> or <i>TREM2</i> develop similar CNS manifestations [<a class="bk_pop" href="#plosl.REF.paloneva.2002.656">Paloneva et al 2002</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</p><p>However, osseous pathology is not always present or diagnosed.</p><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_trem2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figploslTselectedtrem2pathogenicvarian" rid-ob="figobploslTselectedtrem2pathogenicvarian">c.40+3delAGG</a> in the 5' consensus donor <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1 of <i>TREM2</i> has been reported to cause a dementia syndrome resembling PLOSL without evident osseous manifestations [<a class="bk_pop" href="#plosl.REF.chouery.2008.e194">Chouery et al 2008</a>].</div></li><li class="half_rhythm"><div>In addition, some <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants in <i>TREM2</i> (<a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_trem2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figploslTselectedtrem2pathogenicvarian" rid-ob="figobploslTselectedtrem2pathogenicvarian">p.Gln33Ter</a>, <a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_trem2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figploslTselectedtrem2pathogenicvarian" rid-ob="figobploslTselectedtrem2pathogenicvarian">p.Thr66Met</a>, and <a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_trem2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figploslTselectedtrem2pathogenicvarian" rid-ob="figobploslTselectedtrem2pathogenicvarian">p.Tyr38Cys</a>) have been reported to present as a frontotemporal dementia-like syndrome with CNS manifestations typical of PLOSL but without bone involvement [<a class="bk_pop" href="#plosl.REF.guerreiro.2013c.78">Guerreiro et al 2013c</a>].</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_trem2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figploslTselectedtrem2pathogenicvarian" rid-ob="figobploslTselectedtrem2pathogenicvarian">p.Gln33Ter</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has also been reported in a patient with PLOSL. This patient presented with the typical radiologic bone pathology but fractures were not diagnosed [<a class="bk_pop" href="#plosl.REF.bock.2013.115">Bock et al 2013</a>]. The homozygous <a class="figpopup" href="/books/NBK1197/table/plosl.T.selected_trem2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figploslTselectedtrem2pathogenicvarian" rid-ob="figobploslTselectedtrem2pathogenicvarian">p.Thr66Met</a> pathogenic variant was reported in a family with CNS manifestations typical of PLOSL but without diagnosed osseous manifestations [<a class="bk_pop" href="#plosl.REF.le_ber.2014.2419.e23">Le Ber et al 2014</a>].</div></li></ul></div><div id="plosl.Nomenclature"><h3>Nomenclature</h3><p>PLOSL or Nasu-Hakola disease is the recommended name.</p><p>Some authors have preferred the abbreviation "PLO-SL."</p><p>The first <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals were described in the 1960s independently by J&#x000e4;rvi and Hakola in Finland and Nasu in Japan.</p><p>In the early literature, PLOSL was also known as "membranous lipodystrophy." This term is outdated and should not be used.</p></div><div id="plosl.Prevalence"><h3>Prevalence</h3><p>The prevalence of PLOSL is highest in Finland, where it is estimated at 1:1,000,000 to 2:1,000,000 [<a class="bk_pop" href="#plosl.REF.pekkarinen.1998.362">Pekkarinen et al 1998</a>]. The prevalence of PLOSL in other countries is lower; no detailed data on the prevalence elsewhere are available. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been diagnosed in Japan (&#x0003e;100 cases) [<a class="bk_pop" href="#plosl.REF.pekkarinen.1998.362">Pekkarinen et al 1998</a>]. Single families with PLOSL have been diagnosed worldwide [<a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</p></div></div><div id="plosl.Genetically_Related_Allelic_Disord"><h2 id="_plosl_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>No disorders other than those discussed in this <i>GeneReview</i> are known to be caused by mutation of <i>TYROBP</i>.</p><p>Some pathogenic variants in <i>TREM2</i> have been reported to present as a frontotemporal dementia-like syndrome with CNS manifestations typical of PLOSL but without clinical bone involvement (see <a href="#plosl.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a> and <a href="#plosl.Differential_Diagnosis">Differential Diagnosis</a>) [<a class="bk_pop" href="#plosl.REF.chouery.2008.e194">Chouery et al 2008</a>, <a class="bk_pop" href="#plosl.REF.guerreiro.2013c.78">Guerreiro et al 2013c</a>, <a class="bk_pop" href="#plosl.REF.le_ber.2014.2419.e23">Le Ber et al 2014</a>]. It is unclear if the disease caused by these pathogenic variants is a variant of PLOSL or a distinct form of dementia.</p><p>Heterozygous rare variants in <i>TREM2</i> are associated with an increase in the risk of <a href="/books/n/gene/alzheimer/">Alzheimer disease</a> [<a class="bk_pop" href="#plosl.REF.guerreiro.2013b.117">Guerreiro et al 2013b</a>, <a class="bk_pop" href="#plosl.REF.jonsson.2013.107">Jonsson et al 2013</a>, <a class="bk_pop" href="#plosl.REF.jin.2014.5838">Jin et al 2014</a>].</p></div><div id="plosl.Differential_Diagnosis"><h2 id="_plosl_Differential_Diagnosis_">Differential Diagnosis</h2><p>The combination of frontal-type dementia beginning in the fourth decade and radiologically demonstrable polycystic osseous lesions makes it easy to clinically distinguish PLOSL from the established forms of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> and nonfamilial frontotemporal dementia (e.g., Pick's disease, nonspecific frontal lobe degeneration, and the various entities of frontotemporal dementia and parkinsonism linked to <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 17), in several of which pathogenic variants in <i>MAPT</i>, encoding the protein tau, have been reported.</p><p>It should be noted that some pathogenic variants in <i>TREM2</i> have been reported to cause dementia and frontal lobe syndrome typical of PLOSL without osseous manifestations [<a class="bk_pop" href="#plosl.REF.chouery.2008.e194">Chouery et al 2008</a>, <a class="bk_pop" href="#plosl.REF.bock.2013.115">Bock et al 2013</a>, <a class="bk_pop" href="#plosl.REF.guerreiro.2013a.2890.e1">Guerreiro et al 2013a</a>, <a class="bk_pop" href="#plosl.REF.guerreiro.2013c.78">Guerreiro et al 2013c</a>, <a class="bk_pop" href="#plosl.REF.le_ber.2014.2419.e23">Le Ber et al 2014</a>]. Therefore, PLOSL should be considered in all cases of early-onset dementia of unknown origin.</p></div><div id="plosl.Management"><h2 id="_plosl_Management_">Management</h2><div id="plosl.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with PLOSL, the following evaluations are appropriate:</p><ul><li class="half_rhythm"><div>Radiographs of the bones of wrists, hands, ankles, and feet to determine the extent of osseous manifestations of the disease</div></li><li class="half_rhythm"><div>Brain CT and/or MRI to determine the extent of CNS manifestations</div></li><li class="half_rhythm"><div>Neurologic and neuropsychological examination to establish the extent of neurologic impairment and cognitive disturbance</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="plosl.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Only symptomatic treatment is available.</p><p>Relief of pain after curettage and iliac bone grafting of painful lesions in the talus has been reported [<a class="bk_pop" href="#plosl.REF.ar_kan.2014.458728">Ar&#x00131;kan et al 2014</a>]. Supportive orthopedic devices may be of value in individual cases. The fractures have been reported to heal well [<a class="bk_pop" href="#plosl.REF.paloneva.2001.1552">Paloneva et al 2001</a>].</p><p>Epileptic seizures may worsen the individual's condition. Consequently, adequate antiepileptic drugs (AEDs) are important.</p></div><div id="plosl.Prevention_of_Primary_Manifestatio"><h3>Prevention of Primary Manifestations</h3><p>No therapy to delay or halt the progression of the disease is known.</p></div><div id="plosl.Prevention_of_Secondary_Complicati"><h3>Prevention of Secondary Complications</h3><p>Social problems (unemployment, divorce, financial troubles, and alcoholism) and suicidal tendency are often associated with the progression of the disease [<a class="bk_pop" href="#plosl.REF.ilonen.2012.236">Ilonen et al 2012</a>]. Some of the social consequences may be avoided if family members are informed early about the nature of the disorder [<a class="bk_pop" href="#plosl.REF.hakola.1990b.21">Hakola 1990b</a>].</p></div><div id="plosl.Surveillance"><h3>Surveillance</h3><p>The interval of surveillance for bone lesions and neurologic and psychiatric manifestations must be determined individually.</p></div><div id="plosl.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#plosl.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="plosl.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="plosl.Other"><h3>Other</h3><p>Calcium substitution alone has been shown to be ineffective in preventing the development of the osseous manifestations. The effect of bisphosphonates has not been studied.</p><p>It has been speculated that nonsteroidal anti-inflammatory drugs (NSAIDs) could slow the progression of PLOSL; however, clinical trials have not been performed.</p><p>A single individual with PLOSL improved temporarily when taking donepezil [D Hemelsoet, personal observation]. Clinical trials in a series of individuals with PLOSL have not been reported.</p></div></div><div id="plosl.Genetic_Counseling"><h2 id="_plosl_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="plosl.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="plosl.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>TREM2</i> or <i>TYROBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div><div class="half_rhythm">Note: The sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual who are under age 40 years are at risk for PLOSL. Polycystic osseous lesions in radiographs of the hands and feet of an at-risk adult suggest the diagnosis.</div></li><li class="half_rhythm"><div class="half_rhythm">Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>TREM2</i> or <i>TYROBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 2/3.</div></li><li class="half_rhythm"><div class="half_rhythm">Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> person are obligate heterozygotes for a <i>TREM2</i> or <i>TYROBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Because of the low <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> in the general population, the risk that an affected individual would have children with a carrier is very low except in genetic isolates.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>TREM2</i> or <i>TYROBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="plosl.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>TREM2</i> or <i>TYROBP</i> pathogenic variants in the family.</p></div><div id="plosl.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being affected or carriers.</div></li></ul><p><b>Testing of at-risk asymptomatic adult relatives</b> of individuals with PLOSL is possible after <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has identified the specific pathogenic variants in the family. Such testing should be performed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>. This testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. Testing of asymptomatic at-risk individuals with nonspecific or equivocal symptoms is predictive testing, not diagnostic testing.</p><p><b>Testing of asymptomatic individuals younger than age 18 years</b> who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p><p>In a family with an established diagnosis of PLOSL, it is appropriate to consider testing of symptomatic individuals regardless of age.</p><p>For more information, see also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="plosl.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>TREM2</i> or <i>TYROBP</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for PLOSL are possible.</p></div></div><div id="plosl.Resources"><h2 id="_plosl_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition/polycystic-lipomembranous-osteodysplasia-with-sclerosing-leukoencephalopathy" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy</a></div></li></ul></div><div id="plosl.Molecular_Genetics"><h2 id="_plosl_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="plosl.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL): Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1197/table/plosl.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__plosl.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_plosl.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_plosl.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_plosl.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_plosl.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_plosl.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_plosl.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/54209" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TREM2</i></a></td><td headers="hd_b_plosl.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=54209" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">6p21<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_plosl.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9NZC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Triggering receptor expressed on myeloid cells 2</a></td><td headers="hd_b_plosl.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TREM2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TREM2</a></td><td headers="hd_b_plosl.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TREM2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TREM2</a></td></tr><tr><td headers="hd_b_plosl.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7305" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TYROBP</i></a></td><td headers="hd_b_plosl.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7305" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19q13<wbr style="display:inline-block"></wbr>​.12</a></td><td headers="hd_b_plosl.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O43914" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TYRO protein tyrosine kinase-binding protein</a></td><td headers="hd_b_plosl.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TYROBP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TYROBP</a></td><td headers="hd_b_plosl.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TYROBP[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TYROBP</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="plosl.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="plosl.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL) (<a href="/omim/221770,604142,605086" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1197/table/plosl.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__plosl.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/221770" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">221770</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY 1; PLOSL1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604142" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604142</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TYRO PROTEIN TYROSINE KINASE-BINDING PROTEIN; TYROBP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605086" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605086</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TREM2</td></tr></tbody></table></div></div><p><b><i>TREM2</i></b></p><p><b>Gene structure.</b>
<i>TREM2</i> consists of five exons and codes for a 693-bp <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a>. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1197/#plosl.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> No normal variants have been reported.</p><p><b>Pathogenic variants.</b> Several <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants have been identified. Most individuals with <i>TREM2</i> pathogenic variants have a previously unknown <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#plosl.REF.paloneva.2002.656">Paloneva et al 2002</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2003.669">Paloneva et al 2003</a>, <a class="bk_pop" href="#plosl.REF.soragna.2003.825">Soragna et al 2003</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>]. Only pathogenic variants found in more than one family are presented here. For a more comprehensive list of published pathogenic variants, see <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al [2005]</a>.</p><ul><li class="half_rhythm"><div><b>c.233G&#x0003e;A,</b> a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the region encoding the extracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>TREM2</i>, results in premature termination of translation with no transmembrane and cytoplasmic domains after 77 amino acids. The pathogenic variant has been reported in two Swedish families with PLOSL [<a class="bk_pop" href="#plosl.REF.paloneva.2003.669">Paloneva et al 2003</a>].</div></li><li class="half_rhythm"><div><b>c.377T&#x0003e;G,</b> a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the region encoding the extracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>TREM2</i>, was found in one Canadian and one British individual with PLOSL, both originating from Sri Lanka [<a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>].</div></li></ul><div id="plosl.T.selected_trem2_pathogenic_varian" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>TREM2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1197/table/plosl.T.selected_trem2_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__plosl.T.selected_trem2_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.40+3delAGG</td><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nucleotide/189458827" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_018965<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/9507203" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_061838<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.113A&#x0003e;G</td><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr38Cys</td></tr><tr><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.197C&#x0003e;T</td><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr66Met</td></tr><tr><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.233G&#x0003e;A</td><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp78Ter</td></tr><tr><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.377T&#x0003e;G</td><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val126Gly</td></tr><tr><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.97C&#x0003e;T&#x000a0;<sup>1</sup></td><td headers="hd_h_plosl.T.selected_trem2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln33Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="plosl.TF.2.1"><p class="no_margin">This variant has been reported to cause a PLOSL with typical bone pathology on radiologic examination but also a frontotemporal dementia-like syndrome without bone pathology on radiographs.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The protein encoded by <i>TREM2</i> has 230 amino acids and is an activating cell-surface receptor that forms a complex with the transmembrane adaptor protein TYROBP (DAP12). TREM2 is expressed by a variety of cells of myeloid origin [<a class="bk_pop" href="#plosl.REF.colonna.2003.445">Colonna 2003</a>]. The natural ligand for TREM2 is unknown.</p><p>The TREM2-TYROBP protein complex regulates the differentiation and function of osteoclasts, the bone-resorbing cells [<a class="bk_pop" href="#plosl.REF.cella.2003.645">Cella et al 2003</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2003.669">Paloneva et al 2003</a>, <a class="bk_pop" href="#plosl.REF.humphrey.2005.50">Humphrey et al 2005</a>]. In the CNS, TREM2 is expressed by microglial cells [<a class="bk_pop" href="#plosl.REF.colonna.2003.445">Colonna 2003</a>, <a class="bk_pop" href="#plosl.REF.kiialainen.2005.314">Kiialainen et al 2005</a>]. The function of TREM2 in the CNS is unknown. TREM2 also activates monocyte-derived dendritic cells and is expressed by macrophages [<a class="bk_pop" href="#plosl.REF.bouchon.2001b.1111">Bouchon et al 2001b</a>, <a class="bk_pop" href="#plosl.REF.colonna.2003.445">Colonna 2003</a>, <a class="bk_pop" href="#plosl.REF.thrash.2009.38">Thrash et al 2009</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Depending on the type of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>: either the defective TREM2 protein is truncated, not translated, or not transported to the cell surface; or the consequences of the pathogenic variant cannot be predicted.</p><p>The differentiation of osteoclasts is impaired in TREM2-deficient individuals, and the cells show reduced bone resorption capability in vitro [<a class="bk_pop" href="#plosl.REF.cella.2003.645">Cella et al 2003</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2003.669">Paloneva et al 2003</a>, <a class="bk_pop" href="#plosl.REF.humphrey.2005.50">Humphrey et al 2005</a>].</p><p><b><i>TYROBP</i> (previously known as <i>DAP12</i>)</b></p><p><b>Gene structure.</b>
<i>TYROBP</i> consists of five exons and codes for a 342-bp <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a>. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1197/#plosl.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Several <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants have been identified. Three of them, c.-2897_276+1334del, p.Met1Thr, and p.Met48TrpfsTer6, have been found in more than one family with PLOSL [<a class="bk_pop" href="#plosl.REF.paloneva.2000.357">Paloneva et al 2000</a>, <a class="bk_pop" href="#plosl.REF.kondo.2002.1105">Kondo et al 2002</a>]. Other pathogenic variants reported in <i>TYROBP</i> have been found in single families only [<a class="bk_pop" href="#plosl.REF.baeta.2002.15">Baeta et al 2002</a>, <a class="bk_pop" href="#plosl.REF.paloneva.2002.656">Paloneva et al 2002</a>, <a class="bk_pop" href="#plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann et al 2005</a>]. A single patient with a <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TYROBP</i> has been reported [<a class="bk_pop" href="#plosl.REF.kuroda.2007.88">Kuroda et al 2007</a>].</p><ul><li class="half_rhythm"><div><b>c.-2897_276+1334del.</b> All Finnish individuals with PLOSL are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for this <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, which has also been found in Swedish and Norwegian families [<a class="bk_pop" href="#plosl.REF.paloneva.2000.357">Paloneva et al 2000</a>, <a class="bk_pop" href="#plosl.REF.tranebjaerg.2000.3196">Tranebjaerg et al 2000</a>]. The 5.3-kb deletion encompasses the first four exons of <i>TYROBP</i>. Because the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1-4 deletion is an <i>Alu-</i>mediated <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> event, the breakpoint is not known precisely; here it is shown at the repetitive sequence at the 5' end of the breakpoint. No <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> encoding TYROBP (DAP12) is produced.</div></li><li class="half_rhythm"><div><b>p.Met1Thr,</b> a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> start methionine <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, has been reported in two Japanese families with PLOSL [<a class="bk_pop" href="#plosl.REF.kondo.2002.1105">Kondo et al 2002</a>]. This pathogenic variant results in conversion of the translation initiation methionine to threonine. No TYROBP (DAP12) polypeptide is produced.</div></li><li class="half_rhythm"><div><b>p.Met48TrpfsTer6,</b> another <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, has been found in a number of Japanese individuals with PLOSL. This single-base <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> creates a frameshift in the <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a>, resulting in a premature termination of the polypeptide chain after 52 amino acids, and changes a functionally critical aspartic acid residue in the transmembrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>. The defective protein is not transported to the cell surface [<a class="bk_pop" href="#plosl.REF.paloneva.2000.357">Paloneva et al 2000</a>, <a class="bk_pop" href="#plosl.REF.kondo.2002.1105">Kondo et al 2002</a>].</div></li></ul><div id="plosl.T.selected_tyrobp_pathogenic_varia" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>TYROBP</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1197/table/plosl.T.selected_tyrobp_pathogenic_varia/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__plosl.T.selected_tyrobp_pathogenic_varia_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-2897_276+1334del&#x000a0;<sup>1</sup><br />(5.3-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>; <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of exons 1-4)</td><td headers="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_003332" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003332<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/4507755" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003323<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2T&#x0003e;C</td><td headers="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met1Thr</td></tr><tr><td headers="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.141delG</td><td headers="hd_h_plosl.T.selected_tyrobp_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met48TrpfsTer6</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="plosl.TF.3.1"><p class="no_margin">Because the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1-4 <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> is an <i>Alu-</i>mediated <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> event, the breakpoint is not known precisely; here it is shown at the repetitive sequence at the 5' end of the breakpoint.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The protein contains 113 amino acids and is a transmembrane adaptor protein that mediates the activation of a wide variety of cells of myeloid and lymphoid origin [<a class="bk_pop" href="#plosl.REF.lanier.1998b.703">Lanier et al 1998b</a>, <a class="bk_pop" href="#plosl.REF.bakker.1999.9792">Bakker et al 1999</a>, <a class="bk_pop" href="#plosl.REF.bouchon.2000.4991">Bouchon et al 2000</a>, <a class="bk_pop" href="#plosl.REF.bouchon.2001a.1103">Bouchon et al 2001a</a>]. On the cell plasma membrane, TYROBP is expressed as a disulfide-bonded homodimer linked to the associated cell surface receptors. Numerous <i>TYROBP</i>-associated cell surface receptors in addition to TREM2 have been reported [<a class="bk_pop" href="#plosl.REF.lanier.1998a.693">Lanier et al 1998a</a>, <a class="bk_pop" href="#plosl.REF.lanier.1998b.703">Lanier et al 1998b</a>, <a class="bk_pop" href="#plosl.REF.bouchon.2000.4991">Bouchon et al 2000</a>, <a class="bk_pop" href="#plosl.REF.dietrich.2000.9">Dietrich et al 2000</a>, <a class="bk_pop" href="#plosl.REF.diefenbach.2002.1142">Diefenbach et al 2002</a>, <a class="bk_pop" href="#plosl.REF.gilfillan.2002.1150">Gilfillan et al 2002</a>, <a class="bk_pop" href="#plosl.REF.lanier.2009.150">Lanier 2009</a>]. The cytoplasmic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of TYROBP contains an immunoreceptor tyrosine-based activation motif (ITAM) which on receptor engagement becomes phosphorylated and binds the cytoplasmic protein tyrosine kinases SYK and ZAP70 [<a class="bk_pop" href="#plosl.REF.lanier.1998b.703">Lanier et al 1998b</a>]. This interaction results in intracellular calcium mobilization and subsequent cellular activation [<a class="bk_pop" href="#plosl.REF.mcvicar.1998.32934">McVicar et al 1998</a>].</p><p>The TYROBP-TREM2 protein complex regulates the differentiation and function of osteoclasts [<a class="bk_pop" href="#plosl.REF.paloneva.2003.669">Paloneva et al 2003</a>, <a class="bk_pop" href="#plosl.REF.humphrey.2004.224">Humphrey et al 2004</a>]. In the CNS, TYROBP is expressed by microglial cells; the exact function of the protein in these cells is unknown [<a class="bk_pop" href="#plosl.REF.kiialainen.2005.314">Kiialainen et al 2005</a>, <a class="bk_pop" href="#plosl.REF.takahashi.2005.647">Takahashi et al 2005</a>, <a class="bk_pop" href="#plosl.REF.thrash.2009.38">Thrash et al 2009</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Depending on the type of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>: either the defective TYROBP protein is truncated, not translated, or not transported to the cell surface; or the consequences of the pathogenic variant cannot be predicted.</p><p>The differentiation of osteoclasts in TYROBP-deficient individuals is impaired, and the osteoclasts show a reduced bone resorption capability in vitro [<a class="bk_pop" href="#plosl.REF.paloneva.2003.669">Paloneva et al 2003</a>, <a class="bk_pop" href="#plosl.REF.humphrey.2004.224">Humphrey et al 2004</a>].</p></div><div id="plosl.References"><h2 id="_plosl_References_">References</h2><div id="plosl.Published_Guidelines__Consensus_St"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="plosl.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 11-8-18. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2017. Accessed 11-8-18.</div></li></ul></div><div id="plosl.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.akai.1977.802">Akai M, Tateishi A, Cheng CH, Morii K, Abe M, Ohno T, Ben M. Membranous lipodystrophy: a clinicopathological study of six cases. <span><span class="ref-journal">J Bone Joint Surg Am. </span>1977;<span class="ref-vol">59</span>:802–9.</span> [<a href="/pubmed/908704" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 908704</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.amano.1987.294">Amano N, Iwabuchi K, Sakai H, Yagishita S, Itoh Y, Iseki E, Yokoi S, Arai N, Kinoshita J. Nasu-Hakola's disease (membranous lipodystrophy). <span><span class="ref-journal">Acta Neuropathol. </span>1987;<span class="ref-vol">74</span>:294–9.</span> [<a href="/pubmed/3673522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3673522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.aoki.2011.135">Aoki N, Tsuchiya K, Togo T, Kobayashi Z, Uchikado H, Katsuse O, Suzuki K, Fujishiro H, Arai T, Iseki E, Anno M, Kosaka K, Akiyama H, Hirayasu Y. Gray matter lesions in Nasu-Hakola disease: a report on three autopsy cases. <span><span class="ref-journal">Neuropathology. </span>2011;<span class="ref-vol">31</span>:135–43.</span> [<a href="/pubmed/20880319" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20880319</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.araki.1991.793">Araki T, Ohba H, Monzawa S, Sakuyama K, Hachiya J, Seki T, Takahashi Y, Yamaguchi M. Membranous lipodystrophy: MR imaging appearance of the brain. <span><span class="ref-journal">Radiology. </span>1991;<span class="ref-vol">180</span>:793–7.</span> [<a href="/pubmed/1871295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1871295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.ar_kan.2014.458728">Ar&#x00131;kan M, Y&#x00131;ld&#x00131;r&#x00131;m A, Togral G, Ekmek&#x000e7;i AB. Extremity manifestations and surgical treatment for nasu hakola disease. <span><span class="ref-journal">Case Rep Orthop. </span>2014;<span class="ref-vol">2014</span>:458728.</span> [<a href="/pmc/articles/PMC3965938/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3965938</span></a>] [<a href="/pubmed/24711942" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24711942</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.baeta.2002.15">Baeta E, Guarda C, Mendes I, de Almeida LB, Parreira MJ, Saraiva P, Paloneva J. S&#x000ed;ndroma Nasu-Hakola: um caso portugu&#x000ea;s. <span><span class="ref-journal">Sinapse. </span>2002;<span class="ref-vol">2</span>:15–8.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.bakker.1999.9792">Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1999;<span class="ref-vol">96</span>:9792–6.</span> [<a href="/pmc/articles/PMC22289/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC22289</span></a>] [<a href="/pubmed/10449773" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10449773</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.bird.1983.81">Bird TD, Koerker RM, Leaird BJ, Vlcek BW, Thorning DR. Lipomembranous polycystic osteodysplasia (brain, bone, and fat disease): a genetic cause of presenile dementia. <span><span class="ref-journal">Neurology. </span>1983;<span class="ref-vol">33</span>:81–6.</span> [<a href="/pubmed/6681564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6681564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.bock.2013.115">Bock V, Botturi A, Gaviani P, Lamperti E, Maccagnano C, Piccio L, Silvani A, Salmaggi A. Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL): a new report of an Italian woman and review of the literature. <span><span class="ref-journal">J Neurol Sci. </span>2013;<span class="ref-vol">326</span>:115–9.</span> [<a href="/pubmed/23399524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23399524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.bouchon.2000.4991">Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. <span><span class="ref-journal">J Immunol. </span>2000;<span class="ref-vol">164</span>:4991–5.</span> [<a href="/pubmed/10799849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10799849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.bouchon.2001a.1103">Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. <span><span class="ref-journal">Nature. </span>2001a;<span class="ref-vol">410</span>:1103–7.</span> [<a href="/pubmed/11323674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11323674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.bouchon.2001b.1111">Bouchon A, Hern&#x000e1;ndez-Munain C, Cella M, Colonna M. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. <span><span class="ref-journal">J Exp Med. </span>2001b;<span class="ref-vol">194</span>:1111–22.</span> [<a href="/pmc/articles/PMC2193511/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2193511</span></a>] [<a href="/pubmed/11602640" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11602640</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.cella.2003.645">Cella M, Buonsanti C, Strader C, Kondo T, Salmaggi A, Colonna M. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. <span><span class="ref-journal">J Exp Med. </span>2003;<span class="ref-vol">198</span>:645–51.</span> [<a href="/pmc/articles/PMC2194167/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2194167</span></a>] [<a href="/pubmed/12913093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12913093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.chouery.2008.e194">Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, M&#x000e9;garban&#x000e9; A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. <span><span class="ref-journal">Hum Mutat. </span>2008;<span class="ref-vol">29</span>:E194–E204.</span> [<a href="/pubmed/18546367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18546367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.colonna.2003.445">Colonna M. TREMs in the immune system and beyond. <span><span class="ref-journal">Nat Rev Immunol. </span>2003;<span class="ref-vol">3</span>:445–53.</span> [<a href="/pubmed/12776204" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12776204</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.diefenbach.2002.1142">Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E, Raulet DH. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. <span><span class="ref-journal">Nat Immunol. </span>2002;<span class="ref-vol">3</span>:1142–9.</span> [<a href="/pubmed/12426565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12426565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.dietrich.2000.9">Dietrich J, Cella M, Seiffert M, B&#x000fc;hring HJ, Colonna M. Cutting edge: signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells. <span><span class="ref-journal">J Immunol. </span>2000;<span class="ref-vol">164</span>:9–12.</span> [<a href="/pubmed/10604985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10604985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.gilfillan.2002.1150">Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. <span><span class="ref-journal">Nat Immunol. </span>2002;<span class="ref-vol">3</span>:1150–5.</span> [<a href="/pubmed/12426564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12426564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.guerreiro.2013a.2890.e1">Guerreiro R, Bilgic B, Guven G, Br&#x000e1;s J, Rohrer J, Lohmann E, Hanagasi H, Gurvit H, Emre M. Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. <span><span class="ref-journal">Neurobiol Aging. </span>2013a;<span class="ref-vol">34</span>:2890.e1–5.</span> [<a href="/pmc/articles/PMC3898264/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3898264</span></a>] [<a href="/pubmed/23870839" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23870839</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.guerreiro.2013b.117">Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J., Alzheimer Genetic Analysis Group.  TREM2 variants in Alzheimer's disease. <span><span class="ref-journal">N Engl J Med. </span>2013b;<span class="ref-vol">368</span>:117–27.</span> [<a href="/pmc/articles/PMC3631573/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3631573</span></a>] [<a href="/pubmed/23150934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23150934</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.guerreiro.2013c.78">Guerreiro RJ, Lohmann E, Br&#x000e1;s JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, Emre M, Singleton A, Hardy J. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. <span><span class="ref-journal">JAMA Neurol. </span>2013c;<span class="ref-vol">70</span>:78–84.</span> [<a href="/pmc/articles/PMC4001789/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4001789</span></a>] [<a href="/pubmed/23318515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23318515</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.hakola.1972.1">Hakola HP. Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. <span><span class="ref-journal">Acta Psychiatr Scand Suppl. </span>1972;<span class="ref-vol">232</span>:1–173.</span> [<a href="/pubmed/4509294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4509294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.hakola.a">Hakola HP. Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (membranous lipodystrophy): a neuropsychiatric follow-up study. In: Henriksson M, Huttunen M, Kuoppasalmi K, Lindfors O, Lonnqvist J, eds. <em>Monographs of Psychiatria Fennica.</em> Monograph 17. Helsinki, Finland: Foundation for Psychiatric Research; 1990a:1-114.</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.hakola.1990b.21">Hakola HP. Psychosocial reactions in the spouses of patients suffering polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. <span><span class="ref-journal">J Clin Psychiatry. </span>1990b;<span class="ref-vol">51</span>:21–4.</span> [<a href="/pubmed/2295586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2295586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.hakola.1998.39">Hakola HP. Benton's Visual Retention Test in patients with polycystic lipomembranous dysplasia with sclerosing leukoencephalopathy. <span><span class="ref-journal">Dement Geriatr Cogn Disord. </span>1998;<span class="ref-vol">9</span>:39–43.</span> [<a href="/pubmed/9469264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9469264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.hakola.1983.515">Hakola HP, Partanen VS. Neurophysiological findings in the hereditary presenile dementia characterised by polycystic lipomembranous osteodysplasia and sclerosing leukoencephalopathy. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1983;<span class="ref-vol">46</span>:515–20.</span> [<a href="/pmc/articles/PMC1027441/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1027441</span></a>] [<a href="/pubmed/6410004" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6410004</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.hakola.1993.370">Hakola HP, Puranen M. Neuropsychiatric and brain CT findings in polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. <span><span class="ref-journal">Acta Neurol Scand. </span>1993;<span class="ref-vol">88</span>:370–5.</span> [<a href="/pubmed/8296538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8296538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.humphrey.2005.50">Humphrey MB, Lanier LL, Nakamura MC. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. <span><span class="ref-journal">Immunol Rev. </span>2005;<span class="ref-vol">208</span>:50–65.</span> [<a href="/pubmed/16313340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16313340</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.humphrey.2004.224">Humphrey MB, Ogasawara K, Yao W, Spusta SC, Daws MR, Lane NE, Lanier LL, Nakamura MC. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. <span><span class="ref-journal">J Bone Miner Res. </span>2004;<span class="ref-vol">19</span>:224–34.</span> [<a href="/pubmed/14969392" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14969392</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.ilonen.2012.236">Ilonen T, Hakola P, Vanhanen M, Tiihonen J. Rorschach assessment of personality functioning in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. <span><span class="ref-journal">Acta Neuropsychiatr. </span>2012;<span class="ref-vol">24</span>:236–44.</span> [<a href="/pubmed/25286817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25286817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.ishigooka.1993.179">Ishigooka M, Hashimoto T, Izumiya K, Kodama C, Nakada T. Membranous lipodystrophy (Nasu's disease): a rare cause of neuropathic urinary incontinence. <span><span class="ref-journal">Urol Int. </span>1993;<span class="ref-vol">50</span>:179–81.</span> [<a href="/pubmed/8465487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8465487</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.jin.2014.5838">Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, Bertelsen S, Goate AM, Cruchaga C. Coding variants in TREM2 increase risk for Alzheimer's disease. <span><span class="ref-journal">Hum Mol Genet. </span>2014;<span class="ref-vol">23</span>:5838–46.</span> [<a href="/pmc/articles/PMC4189899/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4189899</span></a>] [<a href="/pubmed/24899047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24899047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.jonsson.2013.107">Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer's disease. <span><span class="ref-journal">N Engl J Med. </span>2013;<span class="ref-vol">368</span>:107–16.</span> [<a href="/pmc/articles/PMC3677583/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3677583</span></a>] [<a href="/pubmed/23150908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23150908</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.kalimo.1994.353">Kalimo H, Sourander P, J&#x000e4;rvi O, Hakola P. Vascular changes and blood-brain barrier damage in the pathogenesis of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (membranous lipodystrophy). <span><span class="ref-journal">Acta Neurol Scand. </span>1994;<span class="ref-vol">89</span>:353–61.</span> [<a href="/pubmed/8085433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8085433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.kiialainen.2005.314">Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. <span><span class="ref-journal">Neurobiol Dis. </span>2005;<span class="ref-vol">18</span>:314–22.</span> [<a href="/pubmed/15686960" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15686960</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.kitajima.1989.35">Kitajima I, Kuriyama M, Usuki F, Izumo S, Osame M, Suganuma T, Murata F, Nagamatsu K. Nasu-Hakola disease (membranous lipodystrophy). Clinical, histopathological and biochemical studies of three cases. <span><span class="ref-journal">J Neurol Sci. </span>1989;<span class="ref-vol">91</span>:35–52.</span> [<a href="/pubmed/2746291" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2746291</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.kl_nemann.2005.1502">Kl&#x000fc;nemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE, Peltonen L, Paloneva J. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">64</span>:1502–7.</span> [<a href="/pubmed/15883308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15883308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.kobayashi.2000.98">Kobayashi K, Kobayashi E, Miyazu K, Muramori F, Hiramatsu S, Aoki T, Nakamura I, Koshino Y. Hypothalamic haemorrhage and thalamus degeneration in a case of Nasu-Hakola disease with hallucinatory symptoms and central hypothermia. <span><span class="ref-journal">Neuropathol Appl Neurobiol. </span>2000;<span class="ref-vol">26</span>:98–101.</span> [<a href="/pubmed/10787346" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10787346</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.kondo.2002.1105">Kondo T, Takahashi K, Kohara N, Takahashi Y, Hayashi S, Takahashi H, Matsuo H, Yamazaki M, Inoue K, Miyamoto K, Yamamura T. Heterogeneity of presenile dementia with bone cysts (Nasu-Hakola disease): three genetic forms. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">59</span>:1105–7.</span> [<a href="/pubmed/12370476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12370476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.kuroda.2007.88">Kuroda R, Satoh J, Yamamura T, Anezaki T, Terada T, Yamazaki K, Obi T, Mizoguchi K. A novel compound heterozygous mutation in the DAP12 gene in a patient with Nasu-Hakola disease. <span><span class="ref-journal">J Neurol Sci. </span>2007;<span class="ref-vol">252</span>:88–91.</span> [<a href="/pubmed/17125796" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17125796</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.lanier.2009.150">Lanier LL. DAP10- and DAP12-associated receptors in innate immunity. <span><span class="ref-journal">Immunol Rev. </span>2009;<span class="ref-vol">227</span>:150–60.</span> [<a href="/pmc/articles/PMC2794881/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2794881</span></a>] [<a href="/pubmed/19120482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19120482</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.lanier.1998a.693">Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. <span><span class="ref-journal">Immunity. </span>1998a;<span class="ref-vol">8</span>:693–701.</span> [<a href="/pubmed/9655483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9655483</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.lanier.1998b.703">Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. <span><span class="ref-journal">Nature. </span>1998b;<span class="ref-vol">391</span>:703–7.</span> [<a href="/pubmed/9490415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9490415</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.le_ber.2014.2419.e23">Le Ber I, De Septenville A, Guerreiro R, Bras J, Camuzat A, Caroppo P, Lattante S, Couarch P, Kabashi E, Bouya-Ahmed K, Dubois B, Brice A. Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. <span><span class="ref-journal">Neurobiol Aging. </span>2014;<span class="ref-vol">35</span>:2419.e23–5.</span> [<a href="/pmc/articles/PMC4208293/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4208293</span></a>] [<a href="/pubmed/24910390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24910390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.m_kel_.1982.51">M&#x000e4;kel&#x000e4; P, J&#x000e4;rv&#x000ed; O, Hakola P, Virtama P. Radiologic bone changes of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. <span><span class="ref-journal">Skeletal Radiol. </span>1982;<span class="ref-vol">8</span>:51–4.</span> [<a href="/pubmed/7079784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7079784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.matsuo.1982.123">Matsuo T, Suetsugu M, Eguchi M, Sasaki M, Tsuneyoshi M. Membranous lipodystrophy. A case report. <span><span class="ref-journal">Arch Psychiatr Nervenkr. </span>1982;<span class="ref-vol">231</span>:123–30.</span> [<a href="/pubmed/7065860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7065860</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.mcvicar.1998.32934">McVicar DW, Taylor LS, Gosselin P, Willette-Brown J, Mikhael AI, Geahlen RL, Nakamura MC, Linnemeyer P, Seaman WE, Anderson SK, Ortaldo JR, Mason LH. DAP12-mediated signal transduction in natural killer cells. A dominant role for the Syk protein-tyrosine kinase. <span><span class="ref-journal">J Biol Chem. </span>1998;<span class="ref-vol">273</span>:32934–42.</span> [<a href="/pubmed/9830044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9830044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.minagawa.1985.38">Minagawa M, Maeshiro H, Shioda K, Hirano A. Membranous lipodystrophy (Nasu disease): clinical and neuropathological study of a case. <span><span class="ref-journal">Clin Neuropathol. </span>1985;<span class="ref-vol">4</span>:38–45.</span> [<a href="/pubmed/2983919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2983919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.miyazu.1991.414">Miyazu K, Kobayashi K, Fukutani Y, Nakamura I, Hasegawa H, Yamaguchi N, Saitoh T. Membranous lipodystrophy (Nasu-Hakola disease) with thalamic degeneration: report of an autopsied case. <span><span class="ref-journal">Acta Neuropathol. </span>1991;<span class="ref-vol">82</span>:414–9.</span> [<a href="/pubmed/1722609" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1722609</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.motohashi.1995.549">Motohashi N, Shinohara M, Shioe K, Fukuzawa H, Akiyama Y, Kariya T. A case of membranous lipodystrophy (Nasu-Hakola disease) with unique MRI findings. <span><span class="ref-journal">Neuroradiology. </span>1995;<span class="ref-vol">37</span>:549–50.</span> [<a href="/pubmed/8570051" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8570051</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.nasu.1973.539">Nasu T, Tsukahara Y, Terayama K. A lipid metabolic disease-"membranous lipodystrophy"-an autopsy case demonstrating numerous peculiar membrane-structures composed of compound lipid in bone and bone marrow and various adipose tissues. <span><span class="ref-journal">Acta Pathol Jpn. </span>1973;<span class="ref-vol">23</span>:539–58.</span> [<a href="/pubmed/4800725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4800725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.nwawka.2014.1449">Nwawka OK, Schneider R, Bansal M, Mintz DN, Lane J. Membranous lipodystrophy: skeletal findings on CT and MRI. <span><span class="ref-journal">Skeletal Radiol. </span>2014;<span class="ref-vol">43</span>:1449–55.</span> [<a href="/pubmed/24777445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24777445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.paloneva.2001.1552">Paloneva J, Autti T, Raininko R, Partanen J, Salonen O, Puranen M, Hakola P, Haltia M. CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:1552–8.</span> [<a href="/pubmed/11402114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11402114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.paloneva.2000.357">Paloneva J, Kestil&#x000e4; M, Wu J, Salminen A, B&#x000f6;hling T, Ruotsalainen V, Hakola P, Bakker AB, Phillips JH, Pekkarinen P, Lanier LL, Timonen T, Peltonen L. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. <span><span class="ref-journal">Nat Genet. </span>2000;<span class="ref-vol">25</span>:357–61.</span> [<a href="/pubmed/10888890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10888890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.paloneva.2003.669">Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, Haltia M, Konttinen YT, Peltonen L. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. <span><span class="ref-journal">J Exp Med. </span>2003;<span class="ref-vol">198</span>:669–75.</span> [<a href="/pmc/articles/PMC2194176/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2194176</span></a>] [<a href="/pubmed/12925681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12925681</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.paloneva.2002.656">Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, Tranebjaerg L, Konttinen Y, Peltonen L. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:656–62.</span> [<a href="/pmc/articles/PMC379202/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379202</span></a>] [<a href="/pubmed/12080485" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12080485</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.pekkarinen.1998.362">Pekkarinen P, Hovatta I, Hakola P, J&#x000e4;rvi O, Kestil&#x000e4; M, Lenkkeri U, Adolfsson R, Holmgren G, Nylander PO, Tranebjaerg L, Terwilliger JD, L&#x000f6;nnqvist J, Peltonen L. Assignment of the locus for PLO-SL, a frontal-lobe dementia with bone cysts, to 19q13. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:362–72.</span> [<a href="/pmc/articles/PMC1376898/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1376898</span></a>] [<a href="/pubmed/9463329" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9463329</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.solje.2014.1780.e13">Solje E, Hartikainen P, Valori M, Vanninen R, Tiihonen J, Hakola P, Tienari P, Remes A. The C9ORF72 expansion does not affect the phenotype in Nasu-Hkola disease with the DAP12 mutation. <span><span class="ref-journal">Neurobiology of aging. </span>2014;<span class="ref-vol">35</span>:1780.e13–1780.e17.</span> [<a href="/pubmed/24612676" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24612676</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.soragna.2003.825">Soragna D, Papi L, Ratti MT, Sestini R, Tupler R, Montalbetti L. An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2003;<span class="ref-vol">74</span>:825–6.</span> [<a href="/pmc/articles/PMC1738498/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1738498</span></a>] [<a href="/pubmed/12754369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12754369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.takahashi.2005.647">Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. <span><span class="ref-journal">J Exp Med. </span>2005;<span class="ref-vol">201</span>:647–57.</span> [<a href="/pmc/articles/PMC2213053/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2213053</span></a>] [<a href="/pubmed/15728241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15728241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.takeshita.2005.309">Takeshita T, Kaminaga T, Tatsumi T, Hatanaka Y, Furui S. Regional cerebral blood flow in a patient with Nasu-Hakola disease. <span><span class="ref-journal">Ann Nucl Med. </span>2005;<span class="ref-vol">19</span>:309–12.</span> [<a href="/pubmed/16097640" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16097640</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.tanaka.1980.193">Tanaka J. Leukoencephalopathic alteration in membranous lipodystrophy. <span><span class="ref-journal">Acta Neuropathol. </span>1980;<span class="ref-vol">50</span>:193–7.</span> [<a href="/pubmed/7415812" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7415812</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.thrash.2009.38">Thrash JC, Torbett BE, Carson MJ. Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu-Hakola disease. <span><span class="ref-journal">Neurochem Res. </span>2009;<span class="ref-vol">34</span>:38–45.</span> [<a href="/pmc/articles/PMC2655126/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2655126</span></a>] [<a href="/pubmed/18404378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18404378</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.tranebjaerg.2000.3196">Tranebjaerg L, Schrader H, Paloneva J. Polycystic lipomembranous osteodysplasia. <span><span class="ref-journal">Tidsskr Nor Laegeforen. </span>2000;<span class="ref-vol">120</span>:3196.</span> [Article in Norwegian] [<a href="/pubmed/11109371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11109371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.vanhanen.2013.10">Vanhanen M, Hakola P, Ilonen T, Tiihonen J. Word list learning in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. <span><span class="ref-journal">Dement Geriatr Cogn Dis Extra. </span>2013;<span class="ref-vol">3</span>:10–5.</span> [<a href="/pmc/articles/PMC3618099/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3618099</span></a>] [<a href="/pubmed/23569454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23569454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="plosl.REF.verloes.1997.753">Verloes A, Maquet P, Sadzot B, Vivario M, Thiry A, Franck G. Nasu-Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. <span><span class="ref-journal">J Med Genet. </span>1997;<span class="ref-vol">34</span>:753–7.</span> [<a href="/pmc/articles/PMC1051061/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1051061</span></a>] [<a href="/pubmed/9321763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9321763</span></a>]</div></li></ul></div></div><div id="plosl.Chapter_Notes"><h2 id="_plosl_Chapter_Notes_">Chapter Notes</h2><div id="plosl.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 March 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 August 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 April 2009 (jp) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> available on a clinical basis for <i>TYROBP</i> and <i>TREM2</i></div></li><li class="half_rhythm"><div>1 May 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 March 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 January 2002 (me) Review posted live</div></li><li class="half_rhythm"><div>31 October 2001 (jp) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1197</span><span class="label">PMID: <a href="/pubmed/20301376" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301376</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pkd-ar/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/poly/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1197&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1197/?report=reader">PubReader</a></li><li><a href="/books/NBK1197/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1197" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1197" style="display:none" title="Cite this Page"><div class="bk_tt">Paloneva J, Autti T, Hakola P, et al. Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL) 2002 Jan 24 [Updated 2015 Mar 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1197/pdf/Bookshelf_NBK1197.pdf">PDF version of this page</a> (406K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#plosl.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#plosl.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#plosl.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#plosl.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#plosl.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#plosl.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#plosl.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#plosl.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#plosl.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#plosl.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#plosl.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7305[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TYROBP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1475434" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1475434" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1475434" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1475434" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23399524" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL): a new report of an Italian woman and review of the literature.</a><span class="source">[J Neurol Sci. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL): a new report of an Italian woman and review of the literature.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bock V, Botturi A, Gaviani P, Lamperti E, Maccagnano C, Piccio L, Silvani A, Salmaggi A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Neurol Sci. 2013 Mar 15; 326(1-2):115-9. Epub 2013 Feb 9.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11402114" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts.</a><span class="source">[Neurology. 2001]</span><div class="brieflinkpop offscreen_noflow">CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Paloneva J, Autti T, Raininko R, Partanen J, Salonen O, Puranen M, Hakola P, Haltia M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurology. 2001 Jun 12; 56(11):1552-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15883308" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2.</a><span class="source">[Neurology. 2005]</span><div class="brieflinkpop offscreen_noflow">The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Klünemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurology. 2005 May 10; 64(9):1502-7. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23569454" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Word list learning in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy.</a><span class="source">[Dement Geriatr Cogn Dis Extra....]</span><div class="brieflinkpop offscreen_noflow">Word list learning in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Vanhanen M, Hakola P, Ilonen T, Tiihonen J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Dement Geriatr Cogn Dis Extra. 2013 Jan; 3(1):10-5. Epub 2013 Feb 16.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15049507" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects.</a><span class="source">[Cell Mol Neurobiol. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bianchin MM, Capella HM, Chaves DL, Steindel M, Grisard EC, Ganev GG, da Silva Júnior JP, Neto Evaldo S, Poffo MA, Walz R, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cell Mol Neurobiol. 2004 Feb; 24(1):1-24. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301376" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301376" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040e3075f66d18aaa6ff04">Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PL...</a><div class="ralinkpop offscreen_noflow">Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL) - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:34:40-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A67C4E040AEB10000000001590083&amp;ncbi_session=CE8A67C4E040E301_0345SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1197%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1197&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1197/&amp;ncbi_pagename=Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL) - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A67C4E040E301_0345SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>